Medtech: Beta, Multiples & WACC by Sector

← Swipe left or right to move through the sections →

What the numbers say.

The medtech sector has shifted noticeably this month. It is valued notably higher than a month ago: the median EV/EBIT rose to 18.7x and most companies became more expensive, the beta eased to 0.75, and the cost of capital stands at 8.0 %. The sector is more unsettled than in September: the choice of peers and settings moves the value more than it did.

EV/EBIT is the multiple to use

It is the tightest of the multiples the fundamentals explain, a dispersion of 12 % across the 20 companies, and the companies are comparable in growth and ROCE. EV/Sales spreads by 29 % because it carries the margin differences with it.

The beta to use: 5 years, monthly, 0.75

Among the stable settings it has the tightest spread across the 20 companies; R² 16 %, 19 of 20 betas significant, liquid group (median bid-ask spread 0.13 %). It is the smartZebra standard setting. The settings alone move the median beta from 0.48 to 0.75.

The choices weigh little

Ten of the twenty companies move the EV/EBIT median by −14 % to +4 %, the settings by up to 34 %. Medtech sits in the relaxed corner of the map.

Expected growth is not what the market pays for this month

The usual yardsticks for medtech: expected growth and EBIT margin. Expected growth: rejected (rank correlation +0.36 with EV/EBIT (NTM)). EBIT margin: rejected (rank correlation +0.37 with EV/EBIT (NTM)). No other key figure from the statements explains EV/EBIT clearly either – the companies are priced on things the accounts do not show.

EV/EBIT (NTM): median 16.8x → 18.7x

19 more expensive · 0 cheaper

All 19 companies became more expensive: Fresenius Medical Care rose least (+1 %), EssilorLuxottica most (+22 %).

{"m":[["Sartorius Stedim Biotech","28.8","30.7","+7%"],["Tecan Group","26.5","26.9","+2%"],["Ypsomed","21.3","22.7","+7%"],["ConvaTec Group","19.4","21.8","+12%"],["Smith & Nephew","17.8","19.6","+10%"],["Sonova","17.4","19.6","+12%"],["Straumann","18.7","19.6","+4%"],["Carl Zeiss Meditec","18.2","19.5","+7%"],["Ambu","17.0","19.4","+14%"],["EssilorLuxottica","15.4","18.7","+22%"],["Alcon","16.8","18.2","+9%"],["Demant","16.8","18.2","+8%"],["Coloplast","14.3","16.0","+12%"],["Getinge","14.7","15.6","+6%"],["Siemens Healthineers","14.1","15.3","+8%"],["bioMerieux","12.4","14.4","+16%"],["Koninklijke Philips","11.1","12.1","+9%"],["Elekta","10.3","11.3","+10%"],["Fresenius Medical Care","9.9","10.1","+1%"]],"b":[["Straumann","1.47","1.39",80],["Ambu","1.41","1.39",73],["Carl Zeiss Meditec","1.36","1.33",57],["Implantica","1.00","1.10",35],["Sartorius Stedim Biotech","0.99","0.98",36],["Tecan Group","0.98","0.93",68],["Sonova","0.99","0.92",68],["Elekta","0.89","0.84",74],["Ypsomed","0.84","0.82",42],["Getinge","0.88","0.81",64],["Siemens Healthineers","0.70","0.68",56],["Demant","0.67","0.65",50],["Alcon","0.67","0.63",72],["ConvaTec Group","0.66","0.63",64],["EssilorLuxottica","0.71","0.62",48],["Koninklijke Philips","0.59","0.55",50],["bioMerieux","0.58","0.49",32],["Smith & Nephew","0.51","0.49",64],["Fresenius Medical Care","0.42","0.43",58],["Coloplast","0.47","0.42",51]],"w":["bioMerieux","Implantica","Sartorius Stedim Biotech","Ypsomed","EssilorLuxottica"]}

Beta (5 years, monthly): median 0.77 → 0.75

19 of 20 significant

Each line runs from last month’s beta (light dot) to this month’s (blue dot), on the same beta setting.

Do the usual yardsticks hold this month?

The usual yardsticks for medtech, tested on the 20 companies this month.

Expected growth

Rejected

Rank correlation +0.36 with EV/EBIT (NTM) · clear link from +0.60

EBIT margin

Rejected

Rank correlation +0.37 with EV/EBIT (NTM) · clear link from +0.60

Position on the sector map

This sector in gold, the other 19 sectors in blue. Dashed lines at 40 pp are illustrative.

Construction

Chemicals

Utilities

158

Telecom

Media

Travel & Leisure

Retail

Luxury

Consumer Goods

Logistics

Business Serv.

Aero & Defence

Electrical Eq.

Medtech

Pharma

IT Services

Semiconductors

Software

Automotive

Machinery

Medtech

How much the choices move the result

Beta and fit

R² (median)

16 %

Significant betas

19 of 20

Median bid-ask spread

0.13 %

Beta range across settings

0.48–0.75

What moves the value?

Change vs. prior month

+11 % vs. September

Peer impact on the median

−14 % to +4 %

Spread from peer choice (pp)

Spread from beta settings (pp)

Position on the sector map

Relaxed

Cost of capital

Cost of equity (CAPM)

“kE = rf + β · MRP”

rf = base rate, MRP = market risk premium, β = sector median beta.

WACC

“WACC = E/(D+E) · kE + D/(D+E) · kD · (1 − t)”

kD = base rate + credit spread; t = peer-average tax rate.

Tax rate

“t = average tax rate of the 20 peers”

Shown above as Tax rate (%).

Selection rules

Best-fit multiple

“lowest dispersion across the 20 companies”

The reference multiple is used only as a fallback.

Beta setting

“tightest spread among stable settings”

Replaces 5y monthly only if it passes the two-month rule.

Status

“|Δ value| ≤ 1 % and |Δ β| ≤ 0.03 → stable”

Up to ±5 % / ±0.06 → shifted a bit; beyond → shifted noticeably.

Scope

The 20 largest European listed companies by market value with core business in medical devices, diagnostics, dental, hearing and vision; primary listing on a European exchange; banks, insurers, financial services and real estate are excluded.